Savings options for Zepbound - Eli Lilly and Company
Learn more about the Zepbound® savings card (no Gov`t beneficiaries, terms apply), the Zepbound cash option, and LillyDirect™, an online pharmacy solutions option.
Eli Lilly and Company - Zepbound®(tirzepatide)
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …
How do I get Zepbound® (tirzepatide) vials? - medical.lilly.com
Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials.1
Mounjaro® (tirzepatide) injection and Zepbound™️ (tirzepatide ...
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a reduced- …
Zepbound®(tirzepatide) - Eli Lilly and Company
to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. Want to learn more about Zepbound? Only the 2.5 mg and 5 mg doses are available in vials.
Zepbound® (tirzepatide) | Eli Lilly and Company
Zepbound (tirzepatide) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off.
Zepbound ® (tirzepatide) injection - Eli Lilly and Company
Zepbound is a once-weekly injectable prescription medicine for chronic weight management in adults with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 with at least one weight-related comorbid condition.
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
• Use ZEPBOUND exactly as your healthcare provider tells you to. A healthcare provider should show you how to prepare to inject your dose of ZEPBOUND before injecting the first time. • Use ZEPBOUND with a reduced-calorie diet and increased physical activity.
Lilly releases Zepbound® (tirzepatide) single ... - Eli Lilly and …
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.